Brinkman P, Ahmed WM, Gómez C, et al. Exhaled volatile organic compounds as markers for medication use in asthma. Eur Respir J 2020; 55: 1900544.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. EurRespirJ 2014; 43: 343–373.
Mes MA, Katzer CB, Chan AHY, et al. Pharmacists and medication adherence in asthma: a systematic review and meta-analysis. Eur Respir J 2018; 52: 1800485.
Nathan RA, Sorkness CA, Kosinski M, et al. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59–65.
Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control 2. Eur Respir J 1999; 14: 902–907.
Viant MR, Kurland IJ, Jones MR, et al. How close are we to complete annotation of metabolomes? Curr Opin Chem Biol 2017; 36: 64–69.
Schleich FN, Dallinga JW, Henket M, et al. Volatile organic compounds discriminate between eosinophilic and neutrophilic inflammation in vitro. J Breath Res 2016; 10: 016006.
Schleich FN, Zanella D, Stefanuto P-H, et al. Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med 2019; 200: 444–453.
Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: Predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
Heaney LG, Busby J, Bradding P, et al. Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med 2019; 199: 454–464.
Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 2010; 65: 1039–1044.
